PATENT CLAIM ANALYSIS

Application Number: 16282786
Application Type: Utility
Filing Date: 2019-02
Publication Date: 2019-06
Patent Classification: ["424", "192100"]

Abstract:
The present invention relates to a biologic that inhibits angiogenesis. In particular, the present invention relates to fusion proteins that inhibit the integrin activated pathway and one other angiogenic factor-activated pathway, the compositions of these fusion proteins, as well as methods for producing and using the same.

Claim (Index 13):
The fusion protein according to  claim 11  comprising the integrin binding peptide, the Fc domain and the other protein binding peptide from C-terminus to N-terminus or from N-terminus to C-terminus.

Metadata:
- Claim Count in Document: 27.0
- Percentile: 99.0
- Lexical Diversity: 1.44444
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14210354', '14527656', '13842667', '13682470', '13145059']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.74695753400332
- 35 USC 102 Novelty (BERT): 0.5302440580703327
- Combined Prediction Score: 0.7252861864100213
- Mean Citation Score: 347.306236
- Max Citation Score: 352.23074
- Similarity Product: 231.6297218319297

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test